These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 5151306

  • 1. 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa.
    Johansson B, Roos BE.
    Eur J Clin Pharmacol; 1971 Sep; 3(4):232-5. PubMed ID: 5151306
    [No Abstract] [Full Text] [Related]

  • 2. Central monoamine metabolism in Parkinson's disease.
    Chase TN, Ng LK.
    Arch Neurol; 1972 Dec; 27(6):486-91. PubMed ID: 5083866
    [No Abstract] [Full Text] [Related]

  • 3. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK, Sonninen V, Siirtola T.
    Eur Neurol; 1973 Dec; 9(6):349-62. PubMed ID: 4712542
    [No Abstract] [Full Text] [Related]

  • 4. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH, Bowers MB.
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981
    [No Abstract] [Full Text] [Related]

  • 5. Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa.
    Gumpert J, Sharpe D, Curzon G.
    J Neurol Sci; 1973 May; 19(1):1-12. PubMed ID: 4715017
    [No Abstract] [Full Text] [Related]

  • 6. Predictive value of the probenecid test for the effect of L-DOPA therapy in Parkinson's disease.
    Lakke JP, Korf J, Van Praag HM, Schut T.
    Nat New Biol; 1972 Apr 19; 236(68):208-9. PubMed ID: 4553111
    [No Abstract] [Full Text] [Related]

  • 7. On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease.
    Casati C, Agnoli A, Jori A, Dolfini E.
    Z Neurol; 1973 Apr 02; 204(2):149-54. PubMed ID: 4121468
    [No Abstract] [Full Text] [Related]

  • 8. The effect of L-dopa on monoamine metabolites in Parkinson's disease.
    van Woert MH, Bowers MB.
    Experientia; 1970 Apr 02; 26(2):161-3. PubMed ID: 5308739
    [No Abstract] [Full Text] [Related]

  • 9. 3 -Methoxy- 4 -hydroxyphenylethylene glycol in human cerebrospinal fluid.
    Gordon EK, Oliver J.
    Clin Chim Acta; 1971 Nov 02; 35(1):145-50. PubMed ID: 4256760
    [No Abstract] [Full Text] [Related]

  • 10. Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease.
    Rinne UK, Sonninen V.
    Neurology; 1972 Jan 02; 22(1):62-7. PubMed ID: 4550499
    [No Abstract] [Full Text] [Related]

  • 11. Parkinsonism-dementia and amyotrophic lateral sclerosis of Guam. Effect of probenecid on monoamine catabolite levels in cerebrospinal fluid.
    Chase RN, Schnur JA, Brody JA, Gordon EK.
    Arch Neurol; 1971 Jul 02; 25(1):9-13. PubMed ID: 5146413
    [No Abstract] [Full Text] [Related]

  • 12. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA, Dowson JH, Ahmed R, Chow R, Gillingham FJ.
    Confin Neurol; 1972 Jul 02; 34(1):143-8. PubMed ID: 5084388
    [No Abstract] [Full Text] [Related]

  • 13. Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy.
    Korf J, van Praag HM, Schut D, Nienhuis RJ, Lakke JP.
    Eur Neurol; 1974 Jul 02; 12(5-6):340-50. PubMed ID: 4448192
    [No Abstract] [Full Text] [Related]

  • 14. Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson's disease.
    Olsson R, Roos BE.
    Nature; 1968 Aug 03; 219(5153):502-3. PubMed ID: 5668438
    [No Abstract] [Full Text] [Related]

  • 15. 5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome.
    Johansson B, Roos BE.
    Life Sci; 1967 Jul 01; 6(13):1449-54. PubMed ID: 6035772
    [No Abstract] [Full Text] [Related]

  • 16. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN.
    Neurology; 1970 Dec 01; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.